4 citations,
February 2018 in “World journal of surgical oncology”
A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
25 citations,
May 2003 in “Expert Opinion on Therapeutic Patents”
Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
The user is seeking advice on which treatment to add to their current regimen for male pattern baldness. They have previously tried Dutasteride, Nizoral, and oral Minoxidil, but experienced continued hair loss. They are specifically asking for experiences with RU58841, Stemoxydine, or Alfatradiol.
RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.
The conversation discusses using estradiol and its derivatives for hair loss without causing feminization. Users mention alternatives like alfatradiol, topical 17b-Estradiol, and DIM (Diindolylmethane).